Home > Insider Trading > Filing (0001104659-22-002355)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1001316	Tg Therapeutics Inc.	TGTX	Pharmaceutical Preparations (2834)	363898269

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1038977	S Michael Weiss	2 Gansevoort Street, 9Th Floor New York NY 10014	Ceo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-12-15	3,000	$0.00	14,145,852	No	5	G	Direct
Common Stock	Disposition	2021-12-16	700,000	$0.00	13,445,852	No	5	G	Direct
Common Stock	Disposition	2021-12-16	9,000	$0.00	13,436,852	No	5	G	Direct
Common Stock	Acquisiton	2021-12-29	56,394	$0.00	13,493,246	No	4	A	Direct
Common Stock	Disposition	2022-01-04	37,549	$19.20	13,455,697	No	4	S	Direct
Common Stock	Disposition	2022-01-05	30,671	$18.31	10,988,021	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	5	G	Direct
No	5	G	Direct
No	5	G	Direct
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Reflects the transfer of shares of TG Therapeutics stock as a bona fide gift to various 501(c)(3) charitable organizations.
Reflects the transfer of shares of TG Therapeutics stock to various trusts for the benefit of Mr. Weiss' dependents.
Reflects a grant of restricted shares of common stock of TG Therapeutics in lieu of cash compensation owed to Mr. Weiss for the 2021 fiscal year, which will fully vest on January 1, 2024.
In connection with the vesting of 225,000 shares held by Mr. Weiss' dependents on January 1, 2022, these shares were sold by the Company's restricted stock administrator in order to satisfy tax withholding obligations. Mr. Weiss nor his dependents had any discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock.
Includes 2,437,005 shares received as a liquidating distribution from Opus Point Partners, LLC ("Opus"), of which Mr. Weiss was a principal. In prior reports, Mr, Weiss reported beneficial ownership of all 4,874,010 shares held by Opus, even though he only owned 50% of Opus. On December 29, 2021, as part of the dissolution of Opus the shares of TGTX held by Opus were distributed to the underlying Opus owners. As a result of such distribution, the 2,437,005 shares held indirectly by the reporting person are no longer held by the reporting person.